"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4 Market Trends
4. Key Insights
4.1 Prevalence of Parkinson's Disease - For Key Countries, 2018
4.2 Regulatory Scenario - For Key Countries
4.3 Patent Snapshot
4.3 New Product Launch
4.4 Pipeline Analysis
4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships
5. Global Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1 Decarboxylase Inhibitors
5.2.2 DopamineAgonists
5.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
5.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
5.2.5 Others
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.3.1 Oral
5.3.2 Injection
5.3.3 Transdermal
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1 Hospital Pharmacy
5.4.2 Retail Pharmacy
5.4.3 Online Stores
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1 North America
5.5.2 Europe
5.5.3 Asia Pacific
5.5.4 Latin America
5.5.5 Middle East & Africa
6. North America Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1 Decarboxylase Inhibitors
6.2.2 Dopamine Agonists
6.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
6.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
6.2.5 Others
6.3. Market Analysis – By Route of Administration
6.3.1 Oral
6.3.2 Injection
6.3.3 Transdermal
6.4. Market Analysis – By Distribution Channel
6.4.1 Hospital Pharmacy
6.4.2 Retail Pharmacy
6.4.3 Online Stores
6.5. Market Analysis – By Country
6.5.1 U.S.
6.5.2 Canada
7. Europe Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Class
7.2.1 Decarboxylase Inhibitors
7.2.2 Dopamine Agonists
7.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
7.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
7.2.4 Others
7.3. Market Analysis – By Route of Administration
7.3.1 Oral
7.3.2 Injection
7.3.3 Transdermal
7.4. Market Analysis – By Distribution Channel
7.4.1 Hospitals
7.4.2 Retail Pharmacy
7.4.3 Online Stores
7.5. Market Analysis – By Countries/ Sub regions
7.5.1 U.K.
7.5.2 Germany
7.5.3 France
7.5.4 Italy
7.5.5 Spain
7.5.6 Scandinavia
7.5.7 Rest of Europe
8. Asia Pacific Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Class
8.2.1 Decarboxylase Inhibitors
8.2.2 Dopamine Agonists
8.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
8.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
8.2.5 Others
8.3. Market Analysis – By Route of Administration
8.3.1 Oral
8.3.2 Injection
8.3.3 Transdermal
8.4. Market Analysis – By Distribution Channel
8.4.1 Hospitals
8.4.2 Retail Pharmacy
8.4.3 Online Stores
8.5. Market Analysis – By Countries/ Sub regions
8.5.1 Japan
8.5.2 China
8.5.3 India
8.5.4 Australia
8.5.5 Southeast Asia
8.5.6 Rest of Asia Pacific
9. Latin America Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025
9.1. Key Findings / Summary
9.2. Market Analysis – By Drug Class
9.2.1 Decarboxylase Inhibitors
9.2.2 Dopamine Agonists
9.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
9.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
9.2.5 Others
9.3. Market Analysis – By Route of Administration
9.3.1 Oral
9.3.2 Injection
9.3.3 Transdermal
9.4. Market Analysis – By Distribution Channel
9.4.1 Hospitals
9.4.2 Retail Pharmacy
9.4.3 Online Stores
9.5. Market Analysis – By Countries/ Sub regions
9.5.1 Brazil
9.5.2 Mexico
9.6.3 Rest of Latin America
10. Middle East &Africa Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025
10.1. Key Findings / Summary
10.2. Market Analysis – By Drug Class
10.2.1 Decarboxylase Inhibitors
10.2.2 Dopamine Agonists
10.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors
10.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors
10.2.5 Others
10.3. Market Analysis – By Route of Administration
10.3.1 Oral
10.3.2 Injection
10.3.3 Transdermal
10.4. Market Analysis – By Distribution Channel
10.4.1 Hospitals
10.4.2 Retail Pharmacy
10.4.3 Online Stores
10.5. Market Analysis – By Countries/ Sub regions
10.5.1 South Africa
10.5.2 GCC
10.5.3 Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Competition Dashboard
11.4. Comparative Analysis –Major Players
11.5. Company Profiles (Overview,Drug Classes & services, SWOT analysis, Recent developments, strategies,financials (based on availability))
11.5.1 UCB S.A
11.5.2 Pfizer,Inc.
11.5.3 F.Hoffmann-La Roche Ltd
11.5.4 Merck& Co., Inc.
11.5.5 Novartis AG
11.5.6 OrionPharma
11.5.7 TevaPharmaceutical Industries Ltd.
11.5.8 Vertical Pharmaceuticals, LLC
11.5.9 ACADIAPharmaceuticals Inc.
11.5.10 ImpaxLaboratories, Inc.
11.5.11 H.Lundbeck A/S
11.5.12 OtherProminent Players
12. Strategic Recommendations
Related Reports